Use of Novel Plasma and Urinary Biomarkers to Predict the Development of Hepatorenal Syndrome in Cirrhotic Patients
Overview
This study investigated the use of novel plasma and urinary biomarkers to predicte the development of hepatorenal syndrome in patients with advanced cirrhosis. The biomarkers investigated include plasma cystatin C, plasma NGAL, plasma NAG, plasma IL-18, plasma ADMA, plasma BTP, urinary KIM-1 and urinary LFABP. These biomarkers will be checked in advanced cirrhotic patients who have or have not developed hepatorenal syndrome and compared between the two groups. These biomarkers will also be correlated with the occurence of hepatorenal syndrome.
Study Type
- Study Type: Observational
- Study Design
- Time Perspective: Prospective
- Study Primary Completion Date: June 2018
Detailed Description
This study investigated the use of novel plasma and urinary biomarkers to predicte the development of hepatorenal syndrome in patients with advanced cirrhosis. The biomarkers tested include plasma cystatin C, plasma NGAL, plasma NAG, plasma IL-18, plasma ADMA, plasma BTP, urinary KIM-1 and urinary LFABP. These biomarkers will be checked in advanced cirrhotic patients who have or have not developed hepatorenal syndrome and compared between the two groups. These biomarkers will also be correlated with the occurence of hepatorenal syndrome.
Arms, Groups and Cohorts
- Hepatorenal syndrome group
- Patients with advanced cirrhosis who develope hepatorenal syndrome
- Non-hepatorenal syndrome group
- Patients with advanced cirrhosis who do not hepatorenal syndrome
Clinical Trial Outcome Measures
Primary Measures
- Hepatorenal syndrome
- Time Frame: 12 weeks
Secondary Measures
- Mortality
- Time Frame: 6 months
- Chronic renal impairment
- Time Frame: 6 months
Participating in This Clinical Trial
Inclusion Criteria
- Patients with advanced cirrhosis (Child's B or C) referred for liver transplantation – Willing to give informed consent Exclusion Criteria:
- Patients with co-existing renal diseases
Gender Eligibility: All
Minimum Age: 18 Years
Maximum Age: 90 Years
Are Healthy Volunteers Accepted: No
Investigator Details
- Lead Sponsor
- The University of Hong Kong
- Collaborator
- The Hong Kong Society of Nephrology
- Provider of Information About this Clinical Study
- Principal Investigator: Dr. Desmond Yat-Hin Yap, Clinical Assistant Professor – The University of Hong Kong
- Overall Official(s)
- Desmond Yap, MD, Principal Investigator, The University of Hong Kong
- Overall Contact(s)
- Desmond Yap, MD, 85222553879, desmondy@hku.hk
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.